 is a randomized, double-blind, placebo-controlled Phase 0 study comparing one year of palbociclib plus at least five years of standard adjuvant endocrine therapy. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Pfizer Media Contact: Jessica Smith 000-000-0000 Jessica. 